Charles Schwab
VIVO

Charles Schwab’s Meridian Bioscience Inc VIVO Stock Holding History

Charles Schwab’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-327,235
Closed -$10.9M – 3636
2022
Q4 		$10.9M Buy
327,235
+7,847
+2% +$253K ﹤0.01% 1814
2022
Q3 		$10.1M Sell
319,388
-9,015
-3% -$292K ﹤0.01% 1828
2022
Q2 		$9.99M Sell
328,403
-17,314
-5% -$468K ﹤0.01% 1836
2022
Q1 		$8.97M Sell
345,717
-83,000
-19% -$1.97M ﹤0.01% 2015
2021
Q4 		$8.75M Sell
428,717
-153,371
-26% -$2.94M ﹤0.01% 2069
2021
Q3 		$11.2M Buy
582,088
+690
+0.1% +$13.8K ﹤0.01% 1943
2021
Q2 		$12.9M Buy
581,398
+51,682
+10% +$1.1M ﹤0.01% 1867
2021
Q1 		$13.9M Buy
529,716
+36,345
+7% +$864K 0.01% 1766
2020
Q4 		$9.22M Buy
493,371
+1,899
+0.4% +$35.5K ﹤0.01% 1914
2020
Q3 		$8.35M Buy
491,472
+205,080
+72% +$3.99M ﹤0.01% 1805
2020
Q2 		$6.67M Buy
286,392
+16,133
+6% +$234K ﹤0.01% 1891
2020
Q1 		$2.27M Buy
270,259
+4,430
+2% +$37.3K ﹤0.01% 2228
2019
Q4 		$2.6M Sell
265,829
-122,284
-32% -$1.15M ﹤0.01% 2340
2019
Q3 		$3.68M Sell
388,113
-38,233
-9% -$403K ﹤0.01% 2135
2019
Q2 		$5.07M Sell
426,346
-129,628
-23% -$1.56M ﹤0.01% 1965
2019
Q1 		$9.79M Buy
555,974
+97,133
+21% +$1.62M 0.01% 1603
2018
Q4 		$7.97M Buy
458,841
+16,411
+4% +$280K 0.01% 1611
2018
Q3 		$6.59M Sell
442,430
-6,269
-1% -$97.2K ﹤0.01% 1896
2018
Q2 		$7.13M Sell
448,699
-119,062
-21% -$1.78M 0.01% 1818
2018
Q1 		$8.06M Buy
567,761
+96,305
+20% +$1.43M 0.01% 1650
2017
Q4 		$6.6M Buy
471,456
+51,976
+12% +$761K 0.01% 1766
2017
Q3 		$6M Buy
419,480
+17,488
+4% +$250K 0.01% 1781
2017
Q2 		$6.33M Buy
401,992
+10,816
+3% +$156K 0.01% 1670
2017
Q1 		$5.4M Sell
391,176
-80,881
-17% -$1.13M 0.01% 1717
2016
Q4 		$8.36M Buy
472,057
+10,348
+2% +$182K 0.01% 1391
2016
Q3 		$8.91M Buy
461,709
+4,013
+0.9% +$78.5K 0.01% 1251
2016
Q2 		$8.93M Sell
457,696
-32,688
-7% -$641K 0.01% 1160
2016
Q1 		$10.1M Buy
490,384
+30,598
+7% +$603K 0.01% 1047
2015
Q4 		$9.44M Buy
459,786
+54,597
+13% +$1.05M 0.01% 1073
2015
Q3 		$6.93M Buy
405,189
+47,065
+13% +$860K 0.01% 1240
2015
Q2 		$6.68M Buy
358,124
+201,074
+128% +$3.73M 0.01% 1353
2015
Q1 		$3M Buy
157,050
+9,587
+7% +$177K ﹤0.01% 1839
2014
Q4 		$2.43M Buy
147,463
+9,550
+7% +$164K ﹤0.01% 1900
2014
Q3 		$2.44M Sell
137,913
-5,034
-4% -$98.9K ﹤0.01% 1847
2014
Q2 		$2.95M Buy
142,947
+7,002
+5% +$144K 0.01% 1750
2014
Q1 		$2.96M Buy
135,945
+6,460
+5% +$148K 0.01% 1719
2013
Q4 		$3.44M Buy
129,485
+6,926
+6% +$170K 0.01% 1559
2013
Q3 		$2.93M Buy
122,559
+10,331
+9% +$241K 0.01% 1593
2013
Q2 		$2.44M Buy
+112,228
New +$2.42M 0.01% 1636

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Charles Schwab's VIVO Position: Q1 2023 in Review

Charles Schwab sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 327,235 shares — an estimated $10.9M sold.

Charles Schwab first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $13.9M in Q1 2021. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Charles Schwab reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Charles Schwab sold 327,235 Meridian Bioscience Inc shares in Q1 2023, an estimated $10.9M.
  • Charles Schwab first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • Charles Schwab's Meridian Bioscience Inc position peaked at $13.9M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.